Xuantai Pharmaceutical announced that the company received the “Drug Registration Certificate” approved and issued by the State Drug Administration and approved the marketing of injectable isaconazole sulfate. The drug approval number is Sinopharm standard H20256410, and the specification is 0.2g. This drug is suitable for the treatment of invasive aspergillosis and invasive pilomycosis in adults. Sales of original research products in 2024 and the first half of 2025 were 204 million yuan and 172 million yuan respectively. Approval for listing is beneficial to enriching the company's product line and enhancing competitiveness, but the sales situation is uncertain.

Xuantai Pharmaceutical announced that the company received the “Drug Registration Certificate” approved and issued by the State Drug Administration and approved the marketing of injectable isaconazole sulfate. The drug approval number is Sinopharm standard H20256410, and the specification is 0.2g. This drug is suitable for the treatment of invasive aspergillosis and invasive pilomycosis in adults. Sales of original research products in 2024 and the first half of 2025 were 204 million yuan and 172 million yuan respectively. Approval for listing is beneficial to enriching the company's product line and enhancing competitiveness, but the sales situation is uncertain.